BTC Capital Management Inc. Acquires 496 Shares of Eli Lilly and Company $LLY

Key Points

• BTC Capital Management Inc. increased its stake in Eli Lilly and Company by 4.7% during Q2, bringing its total holdings to $8.56 million.
• Eli Lilly's quarterly earnings exceeded expectations with an EPS of $6.31, surpassing the analyst consensus by $0.72, and revenue of $15.56 billion.
• The company's recent quarterly dividend was $1.50 per share, reflecting an annualized dividend yield of 0.8%.

BTC Capital Management Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,998 shares of the company's stock after buying an additional 496 shares during the quarter. BTC Capital Management Inc.'s holdings in Eli Lilly and Company were worth $8,560,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Duquesne Family Office LLC lifted its position in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Corient IA LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $570,000. LS Investment Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares in the last quarter. Cutter Capital Management LP purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $207,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $3.33 during midday trading on Monday, hitting $755.32. The company had a trading volume of 2,524,436 shares, compared to its average volume of 4,097,673. The business's 50 day simple moving average is $738.37 and its two-hundred day simple moving average is $769.80. The stock has a market cap of $714.88 billion, a PE ratio of 49.37, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on LLY shares. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.